Floatz logo

PEGFILGRASTIM

Follicular Helper T-Cell Lymphoma

City of Hope Medical Centerprotein_peptidePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

15 Active assets in the Follicular Helper T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Pralatrexate
Corvus Pharmaceuticals, Inc.
Phase 3BB
Soquelitinib
Corvus Pharmaceuticals, Inc.
Phase 3B
Pembrolizumab
Northwestern University
Phase 2B
FILGRASTIM
City of Hope Medical Center
Phase 3B
Inno-206
City of Hope Medical Center
Phase 2B

View all 18 →

Same molecule, other indications

PEGFILGRASTIM is also rated in:

Chemotherapy-induced NeutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
neutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →